Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015028 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00015028: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00015028 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015028, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment. The developmental objective for this combination product is an expansion of therapeutic options for the treatment of opiate dependence.
Interventions
- DRUG Buprenorphine/naloxone
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-11 |
| Est. Completion | 1997-01 |
| Phase | Phase 2 |
What the finished NCT00015028 record still lists
NCT00015028 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00015028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00015028 about?
NCT00015028 is a clinical study titled "Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1". The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment. The developmental objective for this combination product is an expansion of therapeutic options for the treatment of...
What is the current status of trial NCT00015028?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-11. Estimated completion is 1997-01.
What interventions are being tested in trial NCT00015028?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00015028?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia